A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

Start Date01 Jan 2027

Sponsor / Collaborator

University Hospitals of North Midlands NHS Trust

CTRI/2026/05/110976

/ Not yet recruitingNot ApplicableIIT

Evaluation Of Depigmentation by Ceramic Soft Tissue Trimming Bur with and Without Vitamin C Injection - A Split Mouth Clinical Study. - NIL

Start Date24 Sep 2026

Sponsor / Collaborator-

CTRI/2026/03/105930

/ Not yet recruitingPhase 3IIT

A Randomized Controlled Study to Evaluate the Efficacy of Quadruple Fortified Salt (Iron, Iodine, Folic Acid, and Vitamin B12) in Improving Anaemia and Micronutrient Status among Early Adolescent, Women of Reproductive age, and Women aged 50 and above in Southern India: Salt Fortification for Nutritional Enhancement and Hematologic Advancement (SNEHA) Trial - SNEHA Trial

Start Date01 Sep 2026

Sponsor / Collaborator

Cornell University

100 Clinical Results associated with Ascorbic Acid

100 Translational Medicine associated with Ascorbic Acid

100 Patents (Medical) associated with Ascorbic Acid

104,921

Literatures (Medical) associated with Ascorbic Acid

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Clinical outcomes of intense pulsed light combined with non-crosslinked sodium hyaluronate, tranexamic acid, and vitamin C mesotherapy for facial photoaging: a retrospective study

Article

Author: Li, Fei ; Xu, Jialu ; Wu, Xixin ; Wu, Yutong ; Qiu, Houhuang ; Xu, Tianhua ; Wang, Fangfang ; Chen, Xi ; Zhong, Ping ; Lin, Qiusheng

BACKGROUND:

Facial photoaging involves structural and functional deterioration across multiple skin layers. Single-modality treatments rarely address pigmentary, vascular, and dermal matrix changes concurrently. Intense pulsed light (IPL) is widely used for the treatment of dyschromia and vascular lesions. Mesotherapy incorporating non-crosslinked sodium hyaluronate (NCSH), tranexamic acid (TXA), and vitamin C (VC) has been introduced to improve skin hydration and related dermal parameters. The present study assessed the efficacy and safety of combining these modalities for facial rejuvenation.

METHODS:

Eighty-four patients underwent three sessions of IPL with mesotherapy. Standardized VISIA imaging was conducted before each treatment (T0, T1, T2) and at 1-2 months (T3) and 3-6 months (T4) post-treatment. Efficacy was assessed using the Modified Fitzpatrick Wrinkle Scale (MFWS) and Global Aesthetic Improvement Scale (GAIS); adverse events and satisfaction were recorded.

RESULTS:

All six VISIA parameters and MFWS scores improved significantly (p __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__<0.001), peaking at T3 with mild non-significant rebound at T4. GAIS and satisfaction assessments confirmed consistent aesthetic improvement. No severe adverse events occurred; transient burning, papular reactions, and erythema were most common. The overall satisfaction rate was 82.15%.

CONCLUSIONS:

IPL combined with NCSH/TXA/VC mesotherapy provided safe, effective, and well-tolerated improvement in facial photoaging, representing a promising multimodal rejuvenation approach.

31 Dec 2026·Journal of the International Society of Sports Nutrition

Micronutrient intake and predictors of adequacy in female collegiate dancers consuming low-energy diets

Article

Author: Jordan, Aydan ; Sanders, David J. ; Saenz, Catherine ; Frost, Ann ; Stroh, Eli ; Vatne, Emaly ; Nickerson, Brett S. ; Calamoneri, Tanya ; Brooks, Samantha

BACKGROUND:

Collegiate dancers face high training loads, aesthetic pressures, and limited access to nutritional resources, elevating their risk for low energy intake and micronutrient insufficiency. Although inadequate micronutrient intake has been documented, prior studies are largely limited to single sites, ballet-focused programs, or short assessment periods, making findings difficult to generalize and leaving long-term habitual intake across diverse collegiate dance styles poorly understood. Given the elevated risk for low energy intake and nutrient inadequacy in this population, further investigation is warranted. This study aimed to evaluate habitual micronutrient intake in female collegiate dancers relative to the Recommended Dietary Allowance (RDA) and sports nutrition guidelines, and to identify dietary predictors of micronutrient adequacy.

METHODS:

Thirty female collegiate dancers from three U.S. university dance programs (mean age = 20.4 years; BMI = 21.1 kg/m²) completed the Diet History Questionnaire III. Total energy and micronutrient intake from food and supplements were quantified for calcium, iron, folate, omega‑3 fatty acids, and vitamins B12, C, and D. Adequacy relative to the RDA/Adequate Intake (AI) was determined for each nutrient. Fisher's exact tests compared adequacy between supplement users and non‑users. Logistic regression models evaluated predictors of meeting the RDA/AI, including total energy intake (per 100 kcal), supplement use, and relevant food‑group intake.

RESULTS:

Most dancers consumed below the RDA/AI for calcium (20/30; 67%), iron (24/30; 80%), vitamin D (20/29; 69%), omega‑3 fatty acids (19/30; 63%), and folate (17/29; 59%). Conversely, a majority met the RDA for vitamin B12 (17/26; 65%) and vitamin C (20/30; 67%). When compared with sports nutrition recommendations, an even greater proportion fell short for calcium (29/30), omega‑3 fatty acids (30/30), vitamin D (22/29), and vitamin C (14/30). Supplement use was significantly associated with meeting the RDA for iron (75% vs. 11.5%; p = 0.018; OR = 19.14), folate (87.5% vs. 23.8%; p = 0.003; OR = 19.61), vitamin B12 (100% vs. 47.1%; p = 0.009; OR = Inf), vitamin C (94.1% vs. 46.2%; p = 0.009; OR = 16.68), and vitamin D (56.3% vs. 0%; p = 0.001; OR = Inf). Total energy intake significantly predicted adequacy for calcium (p = 0.020; OR = 1.27), iron (p = 0.0002; OR = 1.69), omega‑3 fatty acids (p = 0.007; OR = 1.27), folate (p = 0.004; OR = 1.57), and vitamin B12 (p = 0.004; OR = 1.39), but not vitamin C or D. Food‑group intake showed limited predictive value; only red/orange vegetable intake predicted vitamin C adequacy.

CONCLUSIONS:

Inadequate micronutrient intake was highly prevalent among collegiate dancers, particularly for calcium, iron, vitamin D, omega‑3 fatty acids, and folate. Supplement use improved adequacy for several nutrients, yet observed intake distributions suggest supplementation often compensates for, but not necessarily corrects, underlying dietary shortfalls. Total energy intake emerged as a consistent predictor of adequacy across multiple nutrients, underscoring the central role of sufficient energy intake in supporting micronutrient exposure. Even dancers meeting the RDA frequently fell below athlete‑specific recommendations, highlighting the need for targeted strategies that address both energy intake and micronutrient support within collegiate dance programs.

31 Dec 2026·Libyan Journal of Medicine

Multi-targeted pyrazole scaffolds: synthesis, mechanistic insights, and therapeutic potential in anticancer, antioxidant, and anti-inflammatory applications

Article

Author: Ramadan, Sayed K. ; Eissa, Mohamed E. ; Azab, Mohammad E. ; El-Helw, Eman A. E. ; Aljohi, Hasan A ; Alahmadi, Hanadi A. ; Aljameel, Suhailah S. ; Ghareeb, Ahmed ; Yousef, Tarek A. ; Bahattab, Eman Abdullah ; Alatawi, Zinab ; Al-Farraj, Eida S.

Pyrazole derivatives are a class of heterocyclic compounds known to have broad pharmacological effects. This study aimed to synthesize and characterize a new series of pyrazole derivatives and investigate their effects on a series of in vitro assays. Five synthesized compounds were confirmed structurally using standard spectroscopic techniques, and their cytotoxic activity was evaluated against HeLa cells using MTT assay and morphological examination of viability. DNA damage and fragmentation were analyzed using a comet assay, agarose gel electrophoresis, and diphenylamine reaction. Antioxidant properties were evaluated with radical scavenging assays, and anti-inflammatory potential was assessed with in vitro inhibition assays (COX-1/2). Pyrazolethione 5 showed antiproliferative effects at all concentrations, with preserved cell confluence at ≤62.5 µg/mL. It also demonstrates DPPH scavenging activity similar to that of ascorbic acid in a dose-dependent manner, reaching a maximum activity of 85.9% with an IC₅₀ of 48.77. In addition, it demonstrated antioxidant activity, although significantly lower than that of gallic acid, with a maximum scavenging percentage of 83.9% at 1000 μg/mL and an IC₅₀ of 54.97 μg/mL. In the comet assay, the treatment significantly increased DNA fragmentation to 26.2% ± 0.88% from 12.8% ± 0.77% in the control cells (p < 0.01), representing a two-fold induction of apoptosis. The test compound inhibited COX-1 in a dose-dependent manner (86.29% inhibition at 1000 µg/mL), producing an IC₅₀ value of 29.14 ± 0.97 µg/mL, while it produced moderate inhibition of COX-2, 82.03% inhibition at 1000 µg/mL, and had an IC₅₀ value of 51.49 ± 2.13 µg/mL. According to flow cytometry analysis, untreated HeLa cells were mainly in G1 (54.56%) and G0 (34.86%), with fewer cells in S (9.63%), and G2-M (0.94%). In pyrazolethione-treated HeLa cells, G0 accumulation (73.57%) and fewer proliferative phases (S 3.10% and G2-M 2.78%) indicated substantial alteration to the cell cycle. Pyrazolethione 5 demonstrates a favorable safety profile, with minimal cytotoxicity at lower concentrations, and impressive antioxidant and anti-inflammatory activities. The DPPH and gallic acid-like radical scavenging activities, moderate COX-1 and COX-2 inhibition, and DNA fragmentation suggest multiple bioactivities. Furthermore, the compound significantly altered cell cycle progression in HeLa cells, leading to G0/G1 arrest and reduced proliferation. Taken together, the data indicate pyrazolethione 5 is a potential lead compound for further development/investigation as an anticancer and anti-inflammatory agent with low toxicity.

129

News (Medical) associated with Ascorbic Acid

25 Aug 2026

·www.prnewswire.com

Agency Skin Announces Breakthrough Approach to Skin Longevity With New Personalized, Patent-Pending Treatments

New prescription treatments, advanced ingredients, and personalized dermatological care to target skin longevity at the biological core SAN DIEGO, Aug. 25, 2026 /PRNewswire/ -- Agency Skin™, a leader in personalized prescription skincare, today launched its next generation of treatments for skin longevity, debuting a new line of innovative prescription formulas and a patent-pending Skin Smoothing Booster™ featuring an exclusive seven-peptide blend. Continue Reading Agency Skin 2026 Developed by its board-certified dermatologists and scientists, Agency Skin's treatments combine advanced, science-backed ingredients including tretinoin, vitamin C, estriol, rapamycin, hydroquinone, and resveratrol to address the interconnected biological processes associated with visible skin aging. Every patient's prescription formulas and regimen are customized by a licensed medical provider based on their individual needs, goals, medical history, and response to treatment over time. "Driving real results starts with understanding the skin's underlying biology," said Whitney Tolpinrud, MD, FAAD, Board-Certified Dermatologist and Medical Director at Agency Skin. "Two people may have similar concerns about fine lines, firmness, pigmentation, or texture and still need very different treatments. We can personalize not only the prescription actives we prescribe, but their combinations and strengths, and continue to adjust a patient's treatment as their needs change." Agency Skin's New Patent-Pending Prescription Treatments Agency Skin's new prescription lineup addresses multiple signs of visible aging through treatments a licensed medical provider can calibrate with precision, personalizing not just which ingredients to prescribe, but their combinations and strengths for each patient. Agency Night Renew Rx The foundation of Agency Skin's nighttime regimen, Night RenewRx is formulated to target fine lines, firmness, uneven tone, and texture with active ingredients that support cellular turnover and collagen production. Each Night RenewRx formula is tailored by an Agency Skin licensed medical provider with up to four active ingredients. Individual ingredients may include tretinoin, estriol, tranexamic acid, niacinamide, azelaic acid, glycerin, and dexpanthenol. Night RenewRx offers a broad range of tretinoin strengths, including incremental strengths between commonly available doses, from up to 40% stronger and 80% gentler than typical retail pharmacy options. This gives medical providers greater flexibility to personalize treatments based on a patient's skin, goals, and tolerance. Agency Day Defender Rx Day DefenderRx is a personalized daytime antioxidant prescription treatment, developed to help defend against oxidative stress and the visible effects associated with environmental stressors, like UV light and pollution. The formula combines four antioxidants: L-ascorbic acid, or vitamin C, prescribed at concentrations ranging from 10% to 25%, with resveratrol, EGCG (epigallocatechin gallate) derived from green tea, and niacinamide. It is designed to complement nighttime treatment while helping improve the appearance of uneven tone and dullness. Agency Cell Repair Rx Cell RepairRx brings rapamycin, an emerging ingredient in longevity science, into Agency Skin's prescription treatment offerings. The patent-pending formula combines rapamycin and resveratrol, designed to target inflammaging while supporting firmer skin and improved elasticity. Rapamycin calms mTOR — a signaling protein that becomes overactive with age — to reduce inflammation and help cells repair themselves more efficiently. Cell RepairRx is designed as a nightly addition to a patient's Agency Skin regimen. Agency Dark Spot Rx Dark SpotRx is specifically formulated to address hyperpigmentation, including sunspots and melasma, by targeting excess pigment production. Each prescription draws from a range of proven and advanced active ingredients, including hydroquinone in strengths up to 3x higher than typical retail pharmacy options. Additional available actives include azelaic acid, kojic acid, resveratrol, EGCG (epigallocatechin gallate), and hydrocortisone. Agency Eye Revive Rx Developed specifically for the delicate eye area, Eye ReviveRx is a customized nighttime prescription treatment designed to visibly brighten the under-eye area and smooth the appearance of fine lines and crow's feet. Eye ReviveRx formulas contain a precise blend of carefully calibrated ingredients, which may include tretinoin along with ingredients such as dexpanthenol, caffeine, EGCG, and glycerin. Agency Skin's New Regimen Essentials Agency Skin Smoothing Booster (non-Rx) Skin Smoothing Booster is a patent-pending serum powered by an exclusive blend of seven peptides designed to support natural collagen and elastin, visibly smooth fine lines, and complement Agency Skin's personalized prescription treatments. The advanced peptide complex includes 0.5% pure copper peptide GHK-Cu, which gives the serum its distinctive blue hue. Five forms of hyaluronic acid, together with urea and polyglutamic acid, provide multilayer hydration to help leave skin feeling deeply hydrated, plump, and smooth. Together, these advanced ingredients support smoother, healthier-looking skin over time. The Science Behind Agency Skin's Approach to Longevity Agency Skin's new treatments are developed around five interconnected biological pathways associated with visible skin aging: protein degradation, inflammation, cellular repair, oxidative stress, and DNA damage. Each formula is specifically designed around a primary pathway, with secondary support across the others, reflecting the interconnected biology of skin aging. "Skin aging is extraordinarily complex. There isn't one pathway, one ingredient, or one treatment that determines how we age or how we treat it," said Felipe Jimenez, PhD, Head of Scientific Innovation at Agency Skin. "We developed these formulations to address multiple biological processes associated with visible aging, using ingredients that work in complementary ways across a patient's regimen. Personalization allows us to determine not simply which ingredients to use, but how to combine them and at what strengths for an individual patient." The Five Biological Pathways Protein Degradation: Collagen and elastin are essential to firmness, structure, and elasticity. With age, their production and integrity decline, contributing to fine lines, wrinkles, and loss of firmness. Inflammation : Persistent low-grade inflammation, often referred to as "inflammaging," can contribute to collagen and elastin degradation and impaired barrier function. Cellular Repair: Natural renewal and repair processes become less efficient with age, affecting resilience, recovery, texture, and other visible characteristics of healthy-looking skin. Oxidative Stress: UV exposure, pollution, and other environmental stressors generate free radicals that can cause cellular damage and contribute to dullness, uneven tone, and premature visible aging. DNA Damage: Daily exposure, particularly to UV radiation, can cause DNA damage. As damage accumulates and repair mechanisms become less efficient with age, it can disrupt normal skin function and contribute to visible signs of aging. Personalized Dermatological Care, Built Around the Patient The foundation of Agency Skin's model is an ongoing relationship between every patient and a licensed medical provider. Each treatment plan begins with an online medical consultation, during which the provider determines the appropriate prescriptions, ingredients, combinations, and strengths and builds the patient's regimen around them. Patients can communicate directly with their provider, share progress photos, discuss results or concerns, and request adjustments as their needs change. This allows treatment to evolve based on each patient's response over time. Agency Skin Pricing and Availability Personalized prescription treatments start at $110 for a 60-day supply and are available by subscription following a medical consultation. New patients receive 50% off their first 60-day supply. Agency Skin's non-Rx products start at $40 and can be purchased individually or by subscription. All products are backed by a 120-day money-back guarantee (restrictions apply). Beginning today, all new treatments and products are available at AgencySkin.com. About Agency Skin Agency Skin is a leader in personalized prescription skincare, combining advanced treatments with ongoing care from licensed medical providers. Developed by Agency Skin's dermatologists and scientists, every prescription and regimen is designed to address individual needs and support healthy-looking skin and skin longevity. Agency Skin is headquartered in San Diego, CA and serves patients across the United States. SOURCE Agency Skin 21% more press release views with Request a Demo

10 Aug 2026

·www.einpresswire.com

New Preprint Finds Lithium Ascorbate Outperforms Prescription Lithium with Fewer Side Effects

In preclinical studies, this lithium-vitamin C compound showed anti-anxiety and antidepressant-like effects across 4 stress models without weight gain. NEW YORK, NY, UNITED STATES, August 10, 2026 / EINPresswire.com / -- A new research preprint published on Research Square highlights lithium ascorbate as a potential alternative to conventional lithium carbonate, which is limited by a narrow therapeutic window and concerns about organ-related adverse effects. In preclinical studies, this organic compound combining lithium with vitamin C demonstrated anti-anxiety and antidepressant-like effects across four behavioral stress models, outperforming standard comparator treatments without causing significant weight gain. Researchers tested lithium salts’ effects on rodent behavior. The substances tested in the study were: - Lithium carbonate. - Lithium orotate. - Lithium succinate. - Lithium ascorbate. - Ascorbic acid. Lithium carbonate is an inorganic lithium salt that is traditionally used as a prescription medication for bipolar disorder and treatment-resistant depression. However, it has a narrow dosage window where lithium carbonate stays effective and doesn’t cause damage to the body. Professor Olga Gromova, M.D., a clinical pharmacologist and the chief scientific officer for Normotim, said: “Lithium carbonate is inorganic. It is easy and inexpensive to produce, so it is widely used in psychiatry. The body does not fully absorb lithium carbonate, so doctors prescribe higher doses compared to other lithium forms. The more lithium carbonate is present in the body, the more lithium the kidneys must process and excrete through urine.” Organic lithium salts such as lithium orotate and lithium ascorbate are being researched as potential alternatives to lithium carbonate. It appears that organic lithium salts are better absorbed and tolerated than inorganic forms. Dr. Gromova said: “Organic lithium salts such as lithium ascorbate, lithium citrate, and lithium orotate interact more smoothly with biological systems. The molecules bound to lithium in organic salts participate in metabolic pathways, unlike those in inorganic salts.” Lithium ascorbate is a compound of lithium and ascorbic acid (Vitamin C), which possesses distinct properties unlike carbonate or orotate. Ascorbic acid partakes in immune function, collagen production, and cellular metabolism. Experiments Conducted Open field test: Measures locomotion, exploration, and anxiety by recording how an animal navigates a novel open arena. Swimming test: Measures depression-like behavioral despair by timing how long a rodent struggles versus floats in inescapable water. Tail suspension test: Evaluates depression-like behavior by measuring active escape attempts versus passive immobility while a rodent is hung by its tail. Simulated transport stress test: Models relocation stress by exposing animals to controlled motion, vibration, and noise in a lab environment. Across all tests, lithium ascorbate showed the best results as a potential anti-anxiety and antidepressant substance. Lithium ascorbate reduced immobility, increased active or sustained coping, and enhanced locomotor and exploratory activity. It also increased center entries, reduced grooming and defecation, and lowered post-stress adrenaline and norepinephrine. Lithium ascorbate and lithium orotate went head-to-head in the open field test with one big downside for orotate – weight gain. Animals on lithium orotate gained 16.4% in body weight compared to the control group, while lithium ascorbate stayed at 3.2% Limitations of the study Limitations include small samples, unequal elemental lithium exposure, differences in species, dosing and administration, repeated-testing effects, indirect stress markers, and the inability of rodent models to establish clinical efficacy in humans. Vlada Sukhanovskaya Normopharm email us here +1 917-361-1677 Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Result

07 Aug 2026

·www.sciencedaily.com

Vitamin C may fight cancer — but not the way scientists once thought

Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.Linus Pauling was one of the most brilliant scientists of the 20th century. He won two Nobel prizes and transformed our understanding of chemical bonds and the structure of proteins. Late in his career, though, he became famous for something very different: a passionate belief that very high doses of vitamin C could help people with cancer. Many doctors scoffed. When Pauling himself later died of cancer aged 93, he was held up as a classic case of the “halo effect”: being a genius in one field doesn’t guarantee wisdom in another. Half a century on, the story looks more complicated. Pauling was wrong in important ways, but he was not entirely wrong. Modern research is giving vitamin C a second look in cancer, and it turns out that under certain conditions it can behave less like a gentle vitamin and more like a drug. Pauling’s vitamin C story began in the 1970s, when he teamed up with the Scottish doctor Ewan Cameron and gave patients with advanced, incurable cancer very large amounts of vitamin C – first as a drip into a vein, then as tablets. Compared with similar patients who did not get vitamin C, they reported that the vitamin‑treated group lived longer and felt better. For some, they suggested, survival could be several times longer. Two large trials, run by the Mayo Clinic, a leading non-profit medical center in the US, then put this to the test. The results were clear: there was no benefit. Patients who took vitamin C pills lived no longer than those who didn’t. For most oncologists, that was the end of the matter. Vitamin C was filed away with other “alternative” remedies, and Pauling’s late-career crusade was widely seen as a sad mistake. What neither trial’s critics nor defenders noticed at the time: Pauling and Cameron had started with vitamin C into a vein; the Mayo Clinic trials used tablets only. That matters because the gut can only absorb so much vitamin C. Once you reach a modest daily dose, the body simply stops taking in much more. Swallow as many tablets as you like, and the level of vitamin C in your blood levels off. By contrast, a drip into a vein can raise blood levels to tens or even hundreds of times higher than tablets ever could. At those extreme levels, vitamin C starts to behave differently inside the body. At everyday levels, vitamin C acts as an antioxidant: it mops up harmful molecules and protects our cells. At very high levels, especially around tumors, it can flip roles. In laboratory studies, high-dose vitamin C helps generate hydrogen peroxide, a reactive substance that can damage cells. Cancer cells seem especially vulnerable because they are already under stress. They grow rapidly, often in areas with poor blood supply, and produce lots of reactive molecules of their own. Their internal “cleanup” systems are stretched thin. Add a sudden pulse of hydrogen peroxide and many cancer cells tip over the edge: their DNA and energy machinery are damaged and they die. Normal cells, which are under less strain and have better defenses, are more likely to survive. In this way, very high doses of vitamin C behave less like a daily supplement and more like a weak, selective chemotherapy drug. Crucially, the doses needed for this effect cannot be reached with tablets. In people, the evidence is still early and mixed. Small trials have given high-dose vitamin C through a vein to patients with hard-to-treat cancers such as ovarian, pancreatic or brain tumors. So far, many patients can receive large doses several times a week without serious side-effects. Problems can occur, especially in people with poor kidney function or rare inherited conditions, which is why this is not a harmless wellness drip to be sold on the high street. A few studies suggest that adding vitamin C infusions to chemotherapy may help some patients live a little longer or help with side-effects, but other studies show no clear benefit. The trials are small and varied, so we cannot draw firm conclusions. One consistent signal is quality of life: patients given vitamin C alongside chemotherapy often report less fatigue, less pain and fewer side-effects, such as nausea. For someone with advanced cancer, that matters, even if it is not the sweeping cure Pauling once promised. Lab work also hints at subtler roles. Vitamin C is involved in enzymes that influence how our DNA is “marked” and read, and in how cells divide and respond to low oxygen – important in cancer behavior. In some experiments, high vitamin C levels make cancer cells grow less aggressively and make them more sensitive to treatment. There are even early suggestions that vitamin C may help the immune system recognize and attack tumors, though this remains speculative. So, was Pauling right after all? The fairest answer is that he was partly right, for reasons he did not fully understand, and he exaggerated the promise. He was wrong to promote vitamin C tablets as a powerful cure for cancer. Large, careful trials have not found that swallowing high-dose vitamin C helps people with established cancer live longer. He was also wrong to present vitamin C as a near-universal remedy for many illnesses. But he was not entirely wrong to suspect that vitamin C might have a special role in cancer treatment. He sensed, long before we could prove it, that very high doses given into a vein would behave quite differently from ordinary supplements. Modern research has confirmed that intravenous vitamin C reaches much higher levels in the blood and has distinct biological effects. What we do not yet have are large, definitive randomized trials showing that high-dose intravenous vitamin C clearly prolongs life for most cancer patients. Until we do, it should be seen as experimental – promising enough to study, but not proven enough to replace standard therapies. Any use belongs in clinical trials or in carefully supervised medical settings, not in clinics selling expensive “immune boosts.” The “vitamins in cancer” story continues to evolve. If the story of vitamin C and cancer teaches us anything, it is that science rarely moves in straight lines. A bold idea, some flawed early studies, a fierce backlash – and then, years later, a quieter, more careful return to the question. Pauling may never be fully vindicated, but neither was he simply deluded. In his enthusiasm, he may have glimpsed a sliver of truth long before the rest of us knew how to look for it.

100 Deals associated with Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00018	Ascorbic Acid	G01AD03 S01XA15	DB00126

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Iron Overload	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Methemoglobinemia	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Scurvy	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Ascorbic Acid Deficiency	Japan	T’s Pharma Co., Ltd.	31 Jan 1978

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nutritional and Metabolic Diseases	Phase 3	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Shock, Septic	Phase 3	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Colorectal Cancer	Phase 3	Belgium	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	France	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Germany	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Italy	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Poland	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Spain	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	United Kingdom	Norgine Ltd.	01 Oct 2014
Feeding and Eating Disorders	Phase 3	Brazil	EMS SA (Brazil)	01 Oct 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02905591 (XACT-LUNG, CTgov)	Phase 2	Non-Small Cell Lung Cancer	43	Radiation therapy+Ascorbic Acid+Carboplatin+Paclitaxel	gwvoxomkyn = rpnjgvhiky qdohiagedr (zrctssuguu, nuzyvqqkgn - gvnuqhduam) View more	-	31 Jul 2026
NCT02905578 (CTgov)	Phase 2	Adenocarcinoma \| Metastatic Pancreatic Cancer	40	Pharmacological ascorbate+nab-paclitaxel+Gemcitabine (Ascorbate Group)	hmvrqtsitv(jlkrxusggn) = decnhnoral poqiomyqjk (cnhjoisktz, bcocbbjoai - nnawrillze) View more	-	23 Jul 2026
NCT02905578 (CTgov)	Phase 2	Adenocarcinoma \| Metastatic Pancreatic Cancer	40	nab-paclitaxel+Gemcitabine (Control)	hmvrqtsitv(jlkrxusggn) = olifkwlnmm poqiomyqjk (cnhjoisktz, rbfdrdjtje - wtcjklrfju) View more	-	23 Jul 2026
NCT03410030 (AA NABPLAGEM, CTgov)	Phase 1/2	Pancreatic Ductal Adenocarcinoma \| Neoplasm Metastasis \| Metastatic Pancreatic Cancer	17	Ascorbic Acid (Ascorbic Acid 25 g/m^2)	qdnsmkfzvk(bivfvhyfth) = nleshrtzjz dsrwyohnpu (ssubmihfba, 66.3) View more	-	23 Jul 2026
NCT03410030 (AA NABPLAGEM, CTgov)	Phase 1/2		17	Ascorbic Acid (Ascorbic Acid 37.5 g/m^2)	qdnsmkfzvk(bivfvhyfth) = ucdydztiaj dsrwyohnpu (ssubmihfba, 62.0) View more	-	23 Jul 2026
NCT03509662 (VITaCCA, Pubmed \| Intensive Care Med)	Phase 2	Out-Of-Hospital Cardiac Arrest	273	Placebo	oujdtnwvzj(hfgnmhuvjb): Difference = 2.5 (95.0% CI, 0.5 - 4.5), P-Value = 0.01	Negative	01 Jul 2026
NCT03509662 (VITaCCA, Pubmed \| Intensive Care Med)	Phase 2	Out-Of-Hospital Cardiac Arrest	273	Vitamin C 10 g		Negative	01 Jul 2026
NCT04138394 (Pubmed \| JAMA)	Phase 3	Burns	238	Intravenous vitamin C (50 mg/kg every 6 hours for 96 hours)	dufnzdmcxx(xmrddgalnd) = bkljvcexpn gelooffchw (jrzeaoknde ) View more	Negative	10 Jun 2026
NCT04138394 (Pubmed \| JAMA)	Phase 3	Burns	238	Placebo	dufnzdmcxx(xmrddgalnd) = cebavgzhir gelooffchw (jrzeaoknde ) View more	Negative	10 Jun 2026
NCT04046094 (AACR2026)	Phase 1/2	Muscle Invasive Bladder Carcinoma Neoadjuvant	16	Gemcitabine+Carboplatin+Ascorbate	dbpfsmzvks(qjadapqdib) = rlecgglzjm rejorzyejb (hszqkuytez ) View more	Positive	20 Apr 2026
NCT03418038 (LS1781, ASH2025)	Phase 2	Chronic Myelomonocytic Leukemia TET2 mutation	6	High dose IV ascorbic acid with decitabine	awwwbpzyak(yortzczfgg) = Neutropenia (without infection/sepsis) was the only treatment-associated adverse effect seen in 3 (50%, all grade 3) patients. uodsnzlddq (biajdkfjgy ) View more	Positive	06 Dec 2025
NCT04150042 (SHARON, ESMO2025)	Phase 1	Breast Cancer \| Pancreatic Cancer BRCA \| PALB2	12	ascorbic acidBCNUMelphalan + ascorbic acidBCNUMelphalan + ascorbic acidBCNUMelphalanbalamin + ascorbic acidBCNUMelphalanacid (autologous stem cells)	buxwunpwgk(ccthnucqhd) = trbrkgpquo fxdywjcsgm (rvmrjykgmo )	Positive	17 Oct 2025
ASTRO2025	Phase 2	Lung Cancer	34	Pharmacological Ascorbate and Carboplatin/Paclitaxel	esdvebqrtc(bsucrkfawa) = rklmhgdhuh cgzxgdeakx (rlvwtrpuva )	Positive	27 Sep 2025
ALFEO (ESMO_GI2025)	Not Applicable	Mismatch repair-deficient Colonic Cancer Neoadjuvant pMMR	24	High-dose vitamin C (HDVC)	krcyqldjny(ogulbpxnjs) = svsiqubvtu jrplsreqhz (mxtauqgsge )	Positive	03 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis